Iberdomide
- Generic Name
- Iberdomide
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O5
- CAS Number
- 1323403-33-3
- Unique Ingredient Identifier
- 8V66F27X44
- Background
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Multiple Myeloma Treatment Advances: Belantamab Mafodotin's Comeback and New FDA Approvals
• Belantamab mafodotin (Blenrep) was resurrected after being pulled from the market, demonstrating efficacy in combination therapies for relapsed/refractory multiple myeloma.
• Subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) received FDA approval in combination with VRd for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant.
• The FDA expanded the labels of ciltacabtagene autoleucel (cilta-cel; Carvykti) and idecabtagene vicleucel (ide-cel; Abecma) for use in earlier lines of treatment for relapsed or refractory disease.
• Isatuximab combined with VRd showed significantly improved outcomes in transplant-ineligible newly diagnosed multiple myeloma patients, potentially setting a new standard of care.
Talquetamab and Teclistamab Combination Shows Promising Results in Relapsed/Refractory Multiple Myeloma
• Updated results from the Phase 1b RedirecTT-1 study show the combination of talquetamab and teclistamab yields high response rates in relapsed/refractory multiple myeloma patients.
• The bispecific antibody combination demonstrates durable responses and a manageable safety profile, consistent with each agent's monotherapy profile.
• Patients with extramedullary disease, often resistant to standard therapies, also showed meaningful overall response rates and duration of response with the combination.
• The findings support further investigation of talquetamab-based combinations in multiple myeloma treatment, especially for those with limited options.
iTeos Therapeutics' TIGIT Inhibitor Belrestotug Projects $366M Peak Revenue for Solid Tumors by 2038
• iTeos Therapeutics' Belrestotug (EOS-448), a TIGIT-targeting checkpoint inhibitor, is forecasted to reach $366 million in annual US revenue by 2038 for multiple solid tumor indications.
• The intravenous immunotherapy is being developed for various cancers including non-small cell lung cancer, PD-1 resistant melanoma, and head and neck squamous cell carcinoma.
• iTeos faces financial headwinds with a 95.3% revenue decrease in FY2023 and a net loss of $112.6 million, highlighting the critical importance of Belrestotug's clinical development success.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath